U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H47N2O8S.Na
Molecular Weight 594.736
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM TAUROGLYCOCHOLATE

SMILES

[Na+].[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS([O-])(=O)=O

InChI

InChIKey=PUODKHBECQMSKY-QRPKJZHMSA-M
InChI=1S/C28H48N2O8S.Na/c1-16(4-7-24(34)30-15-25(35)29-10-11-39(36,37)38)19-5-6-20-26-21(14-23(33)28(19,20)3)27(2)9-8-18(31)12-17(27)13-22(26)32;/h16-23,26,31-33H,4-15H2,1-3H3,(H,29,35)(H,30,34)(H,36,37,38);/q;+1/p-1/t16-,17+,18-,19-,20+,21+,22-,23+,26+,27+,28-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C28H47N2O8S
Molecular Weight 571.746
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Sodium tauroglycocholate presents in ENZAR FORTE tablet, together with enzymes: amylase, lipase and protease. ENZAR FORTE is indicated for the treatment of the following digestive symptoms: indigestion/dyspepsia; flatulence; bloating; fullness after eating; heartburn; anorexia; hepatic and pancreatic insufficiency; post-operative digestive upsets and convalescence. Discomfort, flatulence, and abdominal colic may result when the bodies own pancreatic enzymes cannot cope with excessive quantities of food consumed. In such cases, the enzymes present in ENZAR FORTE enhance the digestive processes in a natural way, thereby reducing the amount of undigested food available for fermentation & putrefaction. Amylase enzyme helps in the digestion of starch, lipase is involved in the digestion of lipids, and protease is required for digestion of proteins. The advantage of bile salt i.e. sodium tauroglycocholate for improving absorption of fat & fat-soluble vitamins.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Biliary acid transporting system
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Each enteric-coated tablet contains: Amylase activity -15,000 USP units; Lipase activity - 4,000 USP units; Protease activity - 15,000 USP units of (derived from Pancreatin USP) Sodium tauroglycocholate BPC – 65mg (with sugar coating containing essential carminative oils).
As a digestive enzyme: 1 tablet to be sucked (not chewed) for few seconds and then swallowed with every meal. In pancreatic insufficiency: Up to 2 tablets 2-3 times a day can also be given. But dosage is individualized depending on patient’s pancreatic function.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:12:23 GMT 2023
Edited
by admin
on Sat Dec 16 08:12:23 GMT 2023
Record UNII
SR721549U5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM TAUROGLYCOCHOLATE
WHO-DD  
Common Name English
ETHANESULFONIC ACID, 2-((2-(((3.ALPHA.,5.BETA.,7.ALPHA.,12.ALPHA.)-3,7,12-TRIHYDROXY-24-OXOCHOLAN-24-YL)AMINO)ACETYL)AMINO)-, SODIUM SALT (1:1)
Systematic Name English
ETHANESULFONIC ACID, 2-(((((3.ALPHA.,5.BETA.,7.ALPHA.,12.ALPHA.)-3,7,12-TRIHYDROXY-24-OXOCHOLAN-24-YL)AMINO)ACETYL)AMINO)-, MONOSODIUM SALT
Systematic Name English
Sodium tauroglycocholate [WHO-DD]
Common Name English
Code System Code Type Description
EVMPD
SUB15329MIG
Created by admin on Sat Dec 16 08:12:23 GMT 2023 , Edited by admin on Sat Dec 16 08:12:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID20911482
Created by admin on Sat Dec 16 08:12:23 GMT 2023 , Edited by admin on Sat Dec 16 08:12:23 GMT 2023
PRIMARY
SMS_ID
100000078125
Created by admin on Sat Dec 16 08:12:23 GMT 2023 , Edited by admin on Sat Dec 16 08:12:23 GMT 2023
PRIMARY
CAS
11006-55-6
Created by admin on Sat Dec 16 08:12:23 GMT 2023 , Edited by admin on Sat Dec 16 08:12:23 GMT 2023
PRIMARY
PUBCHEM
23688469
Created by admin on Sat Dec 16 08:12:23 GMT 2023 , Edited by admin on Sat Dec 16 08:12:23 GMT 2023
PRIMARY
FDA UNII
SR721549U5
Created by admin on Sat Dec 16 08:12:23 GMT 2023 , Edited by admin on Sat Dec 16 08:12:23 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY